Pharma Markets

US Dry Age-Related Macular Degeneration Market Analysis and Competitive Landscape Highlights

By Fore Pharma | Published Date: May 24, 2020 | On-Demand Data

US Dry Age-Related Macular Degeneration Market Analysis and Competitive Landscape Highlights – 2020, provides comprehensive insights into Dry Age-Related Macular Degeneration pipeline products, Dry Age-Related Macular Degeneration epidemiology, Dry Age-Related Macular Degeneration market valuations and forecast, Dry Age-Related Macular Degeneration drugs sales and competitive landscape in the US.

Research Scope:

– Dry Age-Related Macular Degeneration Pipeline: Drugs in clinical trials for the treatment of Dry Age-Related Macular Degeneration by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
– Dry Age-Related Macular Degeneration Epidemiology: Number of patients diagnosed (prevalence) with Dry Age-Related Macular Degeneration in the US
– Drugs sales: Sales revenues for Dry Age-Related Macular Degeneration drugs in the US
– Market valuations: US Dry Age-Related Macular Degeneration market size for in 2019; find out how the market advanced from 2016 and forecast to 2025
– Drugs market share: Market shares for key Dry Age-Related Macular Degeneration drugs in the US

This research helps executives to

– Support monitoring and reporting national Dry Age-Related Macular Degeneration market analysis and sales trends
– Track competitor drugs sales and market share in the US Dry Age-Related Macular Degeneration market
– Track competitive developments in Dry Age-Related Macular Degeneration market and present key issues and learnings
– Synthesize insights for Dry Age-Related Macular Degeneration market and products to drive business performance
– Answer key business questions about the Dry Age-Related Macular Degeneration market
– Evaluate commercial market opportunity assessment, positioning, and segmentation for Dry Age-Related Macular Degeneration products
– Supports decision making in R&D to long term marketing strategies

Table of Contents


1) Dry Age-Related Macular Degeneration Treatments
2) Dry Age-Related Macular Degeneration Drugs Pipeline
3) US Dry Age-Related Macular Degeneration Epidemiology
4) Marketed Drugs for Dry Age-Related Macular Degeneration in the US
5) Dry Age-Related Macular Degeneration Market Size and Forecast
6) Dry Age-Related Macular Degeneration Drugs Sales and Forecast
7) Dry Age-Related Macular Degeneration Market Competitive Landscape
8) Methodology
9) Contact us

List of Tables


1. Dry Age-Related Macular Degeneration Phase 3 Clinical Trials, 2020
2. Dry Age-Related Macular Degeneration Phase 2 Clinical Trials, 2020
3. Dry Age-Related Macular Degeneration Phase 1 Clinical Trials, 2020
4. Dry Age-Related Macular Degeneration Epidemiology, US, 2016 – 2025
5. Marketed Drugs for Dry Age-Related Macular Degeneration, US, 2019
6. Dry Age-Related Macular Degeneration Market Size and Forecast ($mn), US, 2016 – 2025
7. Dry Age-Related Macular Degeneration Drugs Sales ($mn), US, 2016 – 2025

List of Figures


1. Dry Age-Related Macular Degeneration Epidemiology, US, 2016 – 2025
2. Dry Age-Related Macular Degeneration Market Size and Forecast ($mn), US, 2016 – 2025
3. Dry Age-Related Macular Degeneration Drugs Market Share (%), US, 2019

Format


Dispatch format is XLSX.

Purchase Checkout Added to cart
face
  • Contact Nick
  •  Email
  •  Contact
  • I was looking for specific epidemiology and utilization data for our emerging therapy situation analysis. It was time sensitive. Your team helped me with the right data and methodologies. Thank you very much.
    - Director, Big Pharma

    About

    • About us
    • Research Store
    • Research Store
    • News
    • Contact

    Trusted By
    Top Companies